John Gray - Vertex Pharmaceuticals Senior Vice President Genetic Therapies
| VRTX34 Stock | BRL 619.20 14.62 2.42% |
Insider
John Gray is Senior Vice President Genetic Therapies of Vertex Pharmaceuticals Incorporated since 2019.
| Age | 53 |
| Tenure | 5 years |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lotte Sonderbjerg | Ascendis Pharma AS | 62 | |
| Mirna Vieira | Biomm SA | N/A | |
| Michael Boehler | BIONTECH SE DRN | N/A | |
| Flemming Jensen | Ascendis Pharma AS | 62 | |
| John Oyler | BeiGene | 55 | |
| Sierk Poetting | BIONTECH SE DRN | 50 | |
| Shannon Klinger | Moderna | 52 | |
| Sean Marett | BIONTECH SE DRN | 58 | |
| Stephen MD | Moderna | 47 | |
| Timothy Lee | Ascendis Pharma AS | N/A | |
| Peter Rasmussen | Ascendis Pharma AS | 54 | |
| Kennett Sprogoe | Ascendis Pharma AS | 44 | |
| Xiaobin Wu | BeiGene | 61 | |
| Daniel Maller | BeiGene | N/A | |
| Xiaodong Wang | BeiGene | 60 | |
| Jerh Collins | Moderna | N/A | |
| Sylke Maas | BIONTECH SE DRN | N/A | |
| Lavina CFA | Moderna | N/A | |
| Ryan Richardson | BIONTECH SE DRN | 44 | |
| Michael LLM | Ascendis Pharma AS | 52 | |
| Noubar Afeyan | Moderna | 60 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | ||
| Reshma Kewalramani, President, Chief Executive Officer, Director | ||
| Michael Parini, Executive Vice President Chief Legal and Administrative Officer | ||
| Alan Garber, Independent Director | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Jeffrey MD, Ex Chairman | ||
| MD FASN, Pres CEO | ||
| Stuart BSc, Ex COO | ||
| John Gray, Senior Vice President Genetic Therapies | ||
| Margaret McGlynn, Independent Director | ||
| Diana McKenzie, Independent Director | ||
| Sangeeta Bhatia, Independent Director | ||
| Terrence Kearney, Independent Director | ||
| Nia Tatsis, Senior Vice President Chief Regulatory Officer | ||
| Kristen Ambrose, Tax, Accounting | ||
| Paul Silva, Senior Vice President Controller | ||
| David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer | ||
| Amit Sachdev, Executive Vice President Chief Regulatory Officer and Chief of Staff to the CEO | ||
| Charles Wagner, Chief Financial Officer, Executive Vice President | ||
| Gerald Bruce, Executive Vice President Commercial Operations | ||
| Ourania Tatsis, Ex Officer | ||
| Bruce Sachs, Co-Lead Independent Director | ||
| Susie Lisa, VP Relations | ||
| Lloyd Carney, Independent Director | ||
| Yuchun Lee, Independent Director | ||
| Stuart Arbuckle, Executive Vice President Chief Commercial Officer | ||
| Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | ||
| Jeffrey Leiden, Executive Chairman of the Board |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 372.17 B | |||
| Shares Outstanding | 1.03 B | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 6.20 X | |||
| Price To Sales | 49.16 X | |||
| Revenue | 8.93 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.